Evidence map›Paper›PMID 41108415›Full record

ArticleArchives of microbiology2025

Comparative evaluation of 1,3,5-triazine-2,4,6-triamine biodegradation by Penicillium hetheringtonii and Fusarium sp.

Nancy Kwatra, Jayanthi Abraham

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nancy KwatraMicrobial Biotechnology Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India.
Jayanthi AbrahamMicrobial Biotechnology Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India. jayanthi.abraham@gmail.com.ORCID http://orcid.org/0000-0001-5005-3088

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melamine is a nitrogen rich compound belonging to the triazine family. The excessive use of melamine is one of the major concerns due to its ability to cause nephrotoxicity, and acute, and chronic kidney disease. In the present study, two fungal strains namely Penicillium hetheringtonii AJ6 and Fusarium sp. MDF3 was isolated using the enrichment technique. These strains were screened for their melamine tolerance ability and could tolerate up to 20 mg/L (P. hetheringtonii), and 29 mg/L (Fusarium sp.) of the contaminant. The degradation studied in an aqueous medium proved that Penicillium hetheringtonii and Fusarium sp. could degrade 78% (initial substrate concentration, 14 mg/L; final substrate concentration, 3.08 ± 0.20 mg/L), and 32% (initial substrate concentration, 20 mg/L; final substrate concentration, 13.6 ± 1.78 mg/L) of introduced melamine respectively. The strains degraded melamine into 2-Propen-1-ol, and 5-methyl-2-hexanone. The degradation kinetics study showed that strains followed zero-order model (P. hetheringtonii), and pseudo second-order model (Fusarium sp.) of kinetics. The significance of kinetic models was assessed using p-value which was reported as 0.007 (zero-order model) and 0.005 (pseudo second-order model). The extracellular enzyme studies revealed that the laccase enzyme system could be responsible for the degradation of melamine. Therefore, the study suggests that the strain P. hetheringtonii AJ6 can be used for melamine remediation from contaminated surfaces.

Indexed as

FusariumPenicilliumTriazinesBiodegradation, EnvironmentalKineticsmelamineTriazinesBioremediationContaminantFungiFusariumMelaminePenicillium

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.